Why Twitter Inc (TWTR) Makes Senses From An Investor Standpoint

Anthony DiClemente, analyst at Nomura Securities, was on CNBC to share his thoughts about Twitter Inc (NYSE:TWTR), a social media company whose second-quarter results took many on Wall Street by surprise. Nomura Securities rates Twitter Inc (NYSE:TWTR) a “Buy” and they have a price target of $43 on the stock.


Discussing Twitter’s earnings beating the estimates, DiClemente started by pointing out that the company is still much smaller compared with Facebook Inc (NASDAQ:FB) in terms of users and other measures. As a matter of fact, he said Twitter is currently less than one-fifth of Facebook in terms of user numbers.

However, DiClemente said Twitter Inc (NYSE:TWTR) is an interesting company from the fact that it is sees real pricing power in terms of monetization growth.

“I think when you look at the rate of monetization growth that they put up in the quarter, the fastest rate of growth in the last six quarters. They talked about pricing being up quarter over quarter 18%,” said DiClemente.

That means that Twitter Inc (NYSE:TWTR) is generating increasingly more revenue per users. DiClemente went on to discuss that the main concern for Twitter is about how big it can monetize its resources and grow its users.

“[…] The real question is how big can users be? How big can monetization per user be? Right now on a per user basis Twitter is monetizing by half of what Facebook Inc (NASDAQ:FB) is. I think they can catch up,” observed DiClemente.

As to whether Twitter Inc (NYSE:TWTR) will continue to spend more on Facebook Inc (NASDAQ:FB) ads, about $600 million annually, DiClemente said he believes Twitter spends that much because of the huge audience on Facebook. While Twitter spends $600 million on Facebook ads, Facebook Inc (NASDAQ:FB) on its part spends about $100 million on Twitter.

Twitter Inc (NYSE:TWTR) posted a 124% increase in revenue in the second quarter to $312 million against the estimated $283 million for the quarter.

Disclosure: none

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!